Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

This study will investigate the safety and efficacy of Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with glaucoma or ocular hypertension who have elevated IOP on dorzolamide hydrochloride/timolol maleate combination therapy.

Inclusion Criteria:

• Diagnosis of ocular hypertension or glaucoma in each eye
• Requires IOP-lowering treatment in both eyes

Exclusion Criteria:

• Use of dorzolamide or carbonic anhydrase within 4 weeks
• Any other active ocular disease other than ocular hypertension or glaucoma (eg, uveitis, ocular infections or severe dry eye)
• Required chronic use of ocular medications other than study medication during the study (intermittent use of certain products eg, artificial tears are permitted)
• Use of oral, injectable or topical ophthalmic steroids within 21 days
• Any eye laser surgery within 3 months
• Any intraocular surgery (eg cataract surgery) within 6 months